AUS
NZ
UK
CA
USA
IND
Highlights:
- New CEO James McDonnell appointed and FDA clearance received for PTX-100 Phase 2 clinical trial.
- Successful IND application for PTX-100 Phase 2 trial in r/rCTCL, with immediate initiation.
- Significant progress in CellPryme and OmniCAR development, alongside strong financial position.
Prescient Therapeutics (ASX:PTX) is preparing for a transformative year in 2025, with the appointment of new CEO James McDonnell and the clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PTX-100. The company anticipates a signpost year as it continues to develop PTX-100, a first-in-class inhibitor targeting the RAS-family pathway.
The December quarter was pivotal for Prescient Therapeutics, marked by the successful clearance of its IND application for the PTX-100 Phase 2 clinical trial in relapsed and refractory cutaneous T-cell lymphomas (r/r CTCL). This clearance by the FDA allows for the immediate initiation of the study, a crucial milestone for the company.
During this period, Prescient Therapeutics also made significant strides in the clinical development of CellPryme and the re-engineering of OmniCAR. These advancements have garnered increasing interest from channel and research and development partners.
The company reported a cash and term deposit balance of $8.4 million as of December 31, with an additional $3.7 million received from the R&D Tax Incentive Rebate on January 10.
FDA Clearance Paves the Way Forward
Prescient Therapeutics received clearance from the FDA for its IND application, enabling the Phase 2 clinical trial of PTX-100 to proceed. PTX-100 is designed to inhibit geranylgeranyl transferase-1 (GGT-1), a key enzyme involved in cancer growth. By blocking GGT-1, PTX-100 disrupts oncogenic Ras pathways, preventing the activation of Rho, Rac, and Ral signaling circuits in cancer cells, ultimately leading to apoptosis. It is believed to be the only GGT-1 inhibitor currently in clinical development.
The company dedicated significant resources to preparing the IND application, engaging clinical and industry experts to refine the study design, trial implementation strategy, and responses to FDA inquiries. Prescient Therapeutics is now moving forward with site selection, assessing clinical locations in Australia, the United States, and Europe, with up to 15 sites expected to be activated. Additionally, the company remains interested in exploring PTX-100's potential in Peripheral T-Cell Lymphoma (PTCL) and is evaluating strategies to generate further clinical data in this patient population.
What is PTX-100?
PTX-100 is a first-in-class compound designed to inhibit geranylgeranyl transferase-1 (GGT-1), a key enzyme involved in cancer growth. By blocking GGT-1, PTX-100 disrupts oncogenic Ras pathways, preventing the activation of Rho, Rac, and Ral signaling circuits in cancer cells, ultimately inducing apoptosis. It is believed to be the only GGT-1 inhibitor currently in clinical development.
The compound has demonstrated safety and early clinical activity in a previous Phase 1 study and a recent pharmacokinetics/pharmacodynamics (PK/PD) basket study across hematological and solid malignancies. The FDA has granted PTX-100 Orphan Drug Designation for all T-cell lymphomas and recently approved an IND application for a Phase 2 study focusing on cutaneous T-cell lymphomas.
Momentum-Gaining Platform
Prescient Therapeutics' CellPryme platform continues to gain momentum in both preclinical and clinical development. During the fourth quarter of 2024, the company presented data on cell therapy manufacturing and adjuvant enhancements at the CAR-TCR Summit in Boston and the American Society of Hematology conference in San Diego, generating increased interest in potential collaborations.
Following these engagements, Prescient Therapeutics has initiated multiple partnerships involving CellPryme-M, working with potential collaborators to explore ways to enhance their cell therapy programs. The company intends to provide investors with updates on the progress of these partnerships as developments allow. Additionally, Prescient Therapeutics is in the early stages of evaluating first-in-human clinical trials for CellPryme-A. If initiated, these trials will investigate CellPryme-A’s potential in combination with CAR-T therapies.
Significant progress has been made in OmniCAR development following extensive troubleshooting of technical challenges and the engineering of new, optimized molecular variants. With encouraging results achieved, Prescient Therapeutics will continue development efforts, with further validation work planned.
What is CellPryme?
- CellPryme-M: A novel, clinic-ready technology designed to enhance adoptive cell therapy by shifting T cells towards a central memory phenotype. This improves persistence and increases the ability of cells to locate and penetrate tumors. The process is a non-disruptive, 24-hour step within cell manufacturing. Cell therapies requiring enhanced manufacturing productivity or increased in vivo potency and durability are well-suited for CellPryme-M.
- CellPryme-A: An adjuvant therapy administered alongside cellular immunotherapy to counteract the suppressive tumor microenvironment. It significantly reduces regulatory T cells, promotes CAR-T cell expansion in vivo, and enhances tumor penetration. These improvements result in better tumor cell killing and increased host survival. When used in combination with CellPryme-M pre-treated CAR-T cells, these benefits are further amplified.
New CEO
James McDonnell, the newly appointed CEO, is a seasoned biopharmaceutical executive with over 25 years of experience in the global pharmaceutical industry. McDonnell has a strong focus on blood disorders and hematological malignancies, including myeloma, myelodysplasia, and chronic myeloid leukemia (CML). His strategic leadership has driven outstanding commercial success, underpinned by his ability to cultivate high-performing team cultures.
